STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more

RegulatoryNegative

AI Analysis

Summary

A final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and delivers significantly less savings (96% reduction) compared to the initial proposal. Eli Lilly's obesity drug is mentioned in the context of Medicare pricing discussions.

Outcome Details

Final Medicare rule for lowering doctor-administered drug prices applies to only four companies and saves 96% less than initial proposal

Importance:5/10

Sentiment:

-0.60

Medicare pricingregulatorydrug pricingobesity

Related Companies

$LLY

Read the original article

Published by STAT News on October 1, 2026 1:26 PM

Read Original